Health
Zealand to Broaden Trial of Weight-Loss Drug After Early Success
This article is for subscribers only.
Zealand Pharma A/S plans to push ahead with a broader study of a potential new obesity drug to rival treatments from Novo Nordisk A/S and Eli Lilly & Co. after it showed positive results in an early-stage trial.
Participants who received the drug, dapiglutide, showed a mean weight loss of up to 6.2% after 13 weekly doses, according to Zealand. That rose to 8.3% when adjusted for the fact that those receiving a placebo gained weight.